Plasmalemmal V-ATPase as a Potential Biomarker for Lactoferrin-Based Anticancer Therapy

Area of Science:

• Biochemistry
• Oncology
• Molecular Biology

Background:

• Lactoferrin (Lf) is a milk-derived protein with demonstrated anticancer properties.
• Its therapeutic potential is attributed to selective targeting of cancer cells and a favorable safety profile (GRAS status).
• Understanding Lf's molecular mechanisms is crucial for its clinical application.

Purpose of the Study:

• To identify the molecular targets of Lactoferrin (Lf) in cancer cells.
• To explore the role of V-ATPase in Lf's selective anticancer activity.
• To evaluate plasmalemmal V-ATPase as a potential biomarker for Lf-based cancer therapy.

Main Methods:

• Investigated the interaction between Lactoferrin (Lf) and cancer cells.
• Identified plasmalemmal V-ATPase as a key target of Lf.
• Analyzed the correlation between V-ATPase presence and cancer cell susceptibility to Lf.

Main Results:

• Lactoferrin (Lf) selectively targets cancer cells.
• Plasmalemmal V-ATPase was identified as a critical target of Lf in cancer cells.
• Cancer cell susceptibility to Lf is dependent on the presence of V-ATPase at the plasma membrane.

Conclusions:

• Plasmalemmal V-ATPase is a key mediator of Lactoferrin's (Lf) anticancer effects.
• V-ATPases presence on the plasma membrane can serve as a predictive biomarker for Lf therapy.
• Further validation through preclinical and clinical studies is needed to establish V-ATPase as a clinical biomarker.